Regen BioPharma (RGBPP) EBIAT (2016 - 2025)
Historic EBIAT for Regen BioPharma (RGBPP) over the last 13 years, with Q3 2025 value amounting to -$572469.0.
- Regen BioPharma's EBIAT fell 11143.98% to -$572469.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 million, marking a year-over-year decrease of 4597.7%. This contributed to the annual value of -$1.3 million for FY2025, which is 9072.09% down from last year.
- Per Regen BioPharma's latest filing, its EBIAT stood at -$572469.0 for Q3 2025, which was down 11143.98% from -$167292.0 recorded in Q2 2025.
- In the past 5 years, Regen BioPharma's EBIAT ranged from a high of $67.0 million in Q2 2022 and a low of -$67.1 million during Q1 2022
- Moreover, its 5-year median value for EBIAT was -$130120.0 (2024), whereas its average is -$367323.2.
- The largest annual percentage gain for Regen BioPharma's EBIAT in the last 5 years was 99407.33% (2022), contrasted with its biggest fall of 1527054.91% (2022).
- Quarter analysis of 5 years shows Regen BioPharma's EBIAT stood at $2.6 million in 2021, then tumbled by 38.16% to $1.6 million in 2022, then plummeted by 121.38% to -$349760.0 in 2023, then tumbled by 47.35% to -$515384.0 in 2024, then decreased by 11.08% to -$572469.0 in 2025.
- Its last three reported values are -$572469.0 in Q3 2025, -$167292.0 for Q2 2025, and -$19354.0 during Q1 2025.